“What are the newer approaches to managing resistant hypertension?”

The management of RHYM uses both traditional yams new medicines that are Non Steroidal mimetalocorticoid receptors antagonists, which have been found to be a safe to use in patients that have chronic kidney disease . There is also a dual endothelia receptor antagonist for patients at Fisk for hyperkalemia that has offered blood pressure control. Then there are aldosterone synthase inhibitors but the potassium levels must be watched. The use of an extended dosing of Novel angiotensinogen syntheses inhibitors may help with compliance of medication adherence . Ask your doctor for about these options ..